<DOC>
	<DOCNO>NCT01358526</DOCNO>
	<brief_summary>The primary objective study assess efficacy safety OXN compare placebo opioid-experienced subject moderate severe pain due chronic low back pain require around-the-clock opioid therapy .</brief_summary>
	<brief_title>Efficacy Safety Oxycodone/Naloxone Controlled-release Tablets ( OXN ) Compared Placebo Opioid-experienced Subjects With Moderate Severe Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Inclusion Criteria include : Male female subject ≥ 18 year age moderate severe , chronic low back pain ( last least several hour daily ) predominant pain condition least 3 month prior screen period ; The back pain must relate nonmalignant nonneuropathic condition without radiation proximal radiation ( knee ) ; Subjects must opioid analgesic therapy low back pain : Has ongoing least 4 week prior screen visit , Consists stable opioid regimen total average daily dose equivalent 20 160 mg ( inclusive ) morphine last 2 week prior screen visit . Subjects take tramadol ≥ 100 mg daily stable regimen last 2 week prior screen visit also meet criterion ; Subjects must require continuation opioid analgesic treatment range 40 160 mg ( inclusive ) morphine equivalent daily likely benefit chronic aroundtheclock opioid therapy duration study ; Subjects must average pain last 14 day score ≥ 5 ( 11point numerical rating scale [ NRS ] ) screen visit , current opioid analgesic medication , applicable , nonopioid medication ; Subjects must average pain last 24 hour score ≥ 5 ( 11point NRS ) screen visit , current opioid analgesic medication , applicable , nonopioid medication ; Subjects must willing able compliant protocol , capable subjective evaluation , able read understand questionnaire , willing able use diary per protocol , read , understand , sign write informed consent English . Exclusion Criteria include : Female subject pregnant ( positive serum beta human chorionic gonadotropin [ β hCG ] test ) lactating ; Subjects contraindication history hypersensitivity oxycodone , naloxone , opioids . This include subject experienced common opioid side effect ( e.g. , nausea , constipation ) ; Subjects acute spinal cord compression , acute compression fracture , seronegative spondyloarthropathy , acute nerve root compression , cauda equina compression , fibromyalgia , reflex sympathetic dystrophy causalgia ( complex regional pain syndrome ) , diabetic amyotrophy , meningitis , discitis , back pain due secondary infection , tumor , postherpetic neuralgia ; Subjects gout , unless control stable suppressive treatment colchicine uricacidlowering therapy without attack ≥ 2 year subject use nonsteroidal antiinflammatory drug ( NSAIDs ) COX2 inhibitor regular basis ; Subjects pseudogout , psoriatic arthritis , active Lyme disease , rheumatoid arthritis inflammatory arthritis , neuropathic pain condition ; Subjects surgical procedure direct towards source chronic low back pain within 6 month screen visit plan study ; Subjects history opioid , alcohol , medication , illicit drug abuse addiction ; Subjects receive investigational medication within 30 day first dose study drug ; Subjects currently take , take naloxone , naltrexone , methylnaltrexone , alvimopan within 10 day screen visit ; Subjects receive study drug clinical study oxycodone/naloxone controlledrelease ( OXN ONU ) . Other protocol specific inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Low back pain</keyword>
	<keyword>Chronic pain</keyword>
	<keyword>Opioid</keyword>
	<keyword>Moderate severe chronic low back pain</keyword>
</DOC>